Former Alexion team launches Rallybio with $37M series A

Rare disease play Rallybio LLC raised $37 million in a series A round led by 5AM Ventures, Canaan Partners and New Leaf Venture Partners. Fellow new investor Connecticut Innovations also participated.

The newco is founded by former Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) executives Martin Mackay, Stephen Uden and Jeffrey Fryer. Mackay was Alexion's EVP and global head of R&D, Uden was SVP and head of research and Fryer was VP and chief tax officer...